Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

In a pair of articles published in Lancet Gastroenterology & Hepatology, scientists lay out the case for why we should expand ...

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and ...

Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) ...

A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, ...

Chronic hepatitis B virus (HBV) is an under-recognised global health threat that affects over 250 million individuals, of whom 80% reside in low-income and middle-income countries (LMICs). HBV causes ...

Discover a study comparing HBV- and alcohol-related ACLF, highlighting distinct clinical profiles and the need for aetiology-specific treatment strategies.

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

AAV204, a novel AAV capsid from the AIM™ capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve ...

A deadly virus, transmitted through tick bites, killed one and hospitalized two others as of June, Wisconsin health officials said.